Andrew D Brown, Louis Fisher, Helen J Curtis, Milan Wiedemann, William J Hulme, Victoria Speed, Lisa E M Hopcroft, Christine Cunningham, Ruth E Costello, James B Galloway, Mark D Russell, Katie Bechman, Zeyneb Kurt, Richard Croker, Chris Wood, Alex J Walker, Andrea L Schaffer, Seb C J Bacon, Amir Mehrkar, George Hickman, Chris Bates, Jonathan Cockburn, John Parry, Frank Hester, Sam Harper, Ben Goldacre, Brian MacKenna
AIMS: The COVID-19 pandemic created unprecedented pressure on healthcare services. This study investigates whether disease-modifying antirheumatic drug (DMARD) safety monitoring was affected during the COVID-19 pandemic. METHODS: A population-based cohort study was conducted using the OpenSAFELY platform to access electronic health record data from 24.2 million patients registered at general practices using TPP's SystmOne software. Patients were included for further analysis if prescribed azathioprine, leflunomide or methotrexate between November 2019 and July 2022...
April 8, 2024: British Journal of Clinical Pharmacology